Anesthesia for bariatric surgery

Gastrointestinal and Colorectal Anesthesia

Volumn , Issue , 2016, Pages 181-198

  Thomas, Robert ^a   Bellamy, Mark ^a,b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35948944450     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (127)

1. http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/.
2. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997; 337(6):396-407.
3. Morley JE. Neuropeptide regulation of appetite and weight. Endocr Rev 1987; 8(3):256-287.
4. Figlewicz DP, Schwartz MW, Seeley RJ, et al. Endocrine regulation of food intake and body weight. J Lab Clin Med 1996; 127(4):328-332.
5. Boggiano MM, Chandler PC, Oswald KD, et al. PYY3-36 as an anti-obesity drug target. Obes Rev 2005; 6(4):307-322.
6. Morrison CD, Morton GJ, Niswender KD, et al. Leptin inhibits hypothalamic Npy and Agrp gene expression via a mechanism that requires phosphatidylinositol 3-OH-kinase signaling. Am J Physiol Endocrinol Metab 2005; 289(6):E1051-E1057.
7. Kopelman PG. Obesity as a medical problem. Nature 2000; 404(6778):635-643.
8. Wangensteen T, Undlien D, Tonstad S, Retterstol L. Genetic causes of obesity. Tidsskr Nor Laegeforen 2005; 125(22):3090-3093.
9. Leibel RL, Chung WK, Chua SC Jr. The molecular genetics of rodent single gene obesities. J Biol Chem 1997; 272(51):1937-1940.
10. Leiter EH. Carboxypeptidase E and obesity in the mouse. J Endocrinol 1997; 155(2):211-214.
11. Haslam DW, James WP. Obesity. Lancet 2005; 366(9492):1197-1209.
12. Karmali S, Shaffer E. The battle against the obesity epidemic: is bariatric surgery the perfect weapon? Clin Invest Med 2005; 28:147-156.
13. Banning M. Obesity: pathophysiology and treatment. J R Soc Health 2005; 125(4):163-167.
14. Halford JC, Harrold JA, Lawton CL, Blundell JE. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets 2005; 6(2):201-213.
15. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337(9):581-588.
16. Tomita T, Zhao Q. Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. Chest 2002; 121(2):649-652.
17. Volmar KE, Hutchins GM. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med 2001; 125(12):1555-1561.
18. Wangsness M. Pharmacological treatment of obesity. Past, present, and future. Minn Med 2000; 83(11):21-26.
19. Klein S. Long-term pharmacotherapy for obesity. Obes Res 2004; 12(suppl):163S-166S.
20. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353(20):2111-2120.
21. Pereira JL, Lopez-Pardo F, Parejo J, et al. Study of heart valve function on obese patients treated with sibutramine. Med Clin (Barc) 2002; 118(2):57 (spanish).
22. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346(8):591-602 (review).
23. Derosa G, Cicero AF, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005; 7(1):47-55.
24. Czerwienska B, Kokot F, Franek E, et al. Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects. Pol Arch Med Wewn 2004; 112(6):1415-1423.
25. Harp JB. Orlistat for the long-term treatment of obesity. Drugs Today (Barc) 1999; 35(2):139-145.
26. Frezza EE, Robinson M. Bariatric and associated operations in private and academic practices. Obes Surg 2004; 14(10):1406-1408.
27. Korenkov M, Sauerland S, Junginger T. Surgery for obesity. Curr Opin Gastroenterol 2005; 21(6):679-683.
28. O'Brien PE, Brown WA, Dixon JB. Obesity, weight loss and bariatric surgery. Med J Aust 2005; 183(6):310-314.
29. Alvarez-Leite JI. Nutrient deficiencies secondary to bariatric surgery. Curr Opin Clin Nutr Metab Care 2004; 7(5):569-575.
30. Koenig SM. Pulmonary complications of obesity. Am J Med Sci 2001; 321(4):249-279.
31. Olson AL, Zwillich C. The obesity hypoventilation syndrome. Am J Med 2005; 118(9):948-956.
32. Namyslowski G, Scierski W, Mrowka-Kata K, et al. Sleep study in patients with overweight and obesity. J Physiol Pharmacol 2005; 56(suppl 6):59-65.
33. Bradley TD, Logan AG, Kimoff RJ, et al. CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005(Nov 10); 353(19):2025-2033.
34. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328:1230-1235.
35. Phillips B. Sleep apnea. Underdiagnosed and undertreated. Hosp Pract (Off Ed) 1996; 31:193-194, 197, 201-202.
36. Rajala R, Partinen M, Sane T, et al. Obstructive sleep apnoea syndrome in morbidly obese patients. J Intern Med 1991; 230:125-129.
37. Wake up America: a national sleep alert. Report of the National Commission on Sleep Disorders Research. Washington (DC): U.S. Department of Health and Human Services, 1993.
38. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000(May 11); 342(19):1378-1384.
39. Strollo PJ Jr., Rogers RM. Obstructive sleep apnea. N Engl J Med 1996(Jan 11); 334(2):99-104.
40. Ebeo CT, Benotti PN, Byrd RP Jr., et al. The effect of bi-level positive airway pressure on postoperative pulmonary function following gastric surgery for obesity. Respir Med 2002; 96(9):672-676.
41. Rochester DF, Enson Y. Current concepts in the pathogenesis of the obesityhypoventilation syndrome. Am J Med 1974; 57:402-420.
42. Zwillich CW, Sutton FD, Pierson DJ, et al. Decreased hypoxic ventilatory drive in the obesity-hypoventilation syndrome. Am J Med 1975; 59:343-348.
43. Ray CS, Sue DY, Bray G, et al. Effects of obesity on respiratory function. Am Rev Respir Dis 1984; 128:501-506.
44. Suratt PM, Wilhoit S, Hsiao H, et al. Compliance of chest wall in obese subjects. J Appl Physiol 1984; 57:403-407.
45. Sprung J, Whalley DG, Falcone T, et al. The impact of morbid obesity, pneumoperitoneum, and posture on respiratory system mechanics and oxygenation during laparoscopy. Anesth Analg 2002; 94(5):1345-1350.
46. Sharp JT, Henry JP, Sweany SK, et al. The total work of breathing in normal and obese men. J Clin Invest 1964; 43:728-739.
47. Yap JCH, Watson RA, Gilbey S, et al. Effects of posture on respiratory mechanics in obesity. J Appl Physiol 1995; 79:1199-1205.
48. Kollias J, Boileau RA, Bartlett HL, et al. Pulmonary function and physiological conditioning in lean and obese subjects. Arch Environ Health 1972; 25:146-150.
49. Kress JP, Pohlman AS, Alverdy J, Hall JB. The impact of morbid obesity on oxygen cost of breathing (VO(2RESP)) at rest. Am J Respir Crit Care Med 1999; 160(3):883-886.
50. Weiner P, Waizman J, Weiner M, et al. Influence of excessive weight loss on on after gastroplasty for morbid obesity on respiratory muscle performance. Thorax 1998; 53(1):39-42.
51. Fadell EJ, Richman AD, Ward WW, et al. Fatty infiltration of respiratory muscles in the Pickwickian syndrome. N Engl J Med 1962; 266:861-863.
52. Pelosi P, Croci M, Ravagnan I, et al. Total respiratory system, lung, and chest wall mechanics in sedated-paralyzed postoperative morbidly obese patients. Chest 1996; 109(1):144-151.
53. Pelosi P, Croci M, Ravagnan I, et al. Respiratory system mechanics in sedated, paralyzed, morbidly obese patients. J Appl Physiol 1997; 82(3):811-818.
54. Refsum HE, Holter PH, Lovig T, et al. Pulmonary function and energy expenditure after marked weight loss in obese women: observations before and one year after gastric banding. Int J Obes 1990; 14(2):175-183.
55. Biring MS, Lewis MI, Liu JT, Mohsenifar Z. Pulmonary physiologic changes of morbid obesity. Am J Med Sci 1999; 318(5):293-297.
56. Katz I, Stradling J, Slutsky AS, et al. Do patients with obstructive sleep apnea have thick necks? Am Rev Respir Dis 1990; 141(5 Pt 1):1228-1231.
57. Jones JG, Sapsford DJ, Wheatley RG. Postoperative hypoxaemia: mechanisms and time course. Anaesthesia 1990; 45(7):566-573.
58. Jense HG, Dubin SA, Silverstein PI, O'Leary-Escolas U. Effect of obesity on safe duration of apnea in anesthetized humans. Anesth Analg 1991; 72(1):89-93.
59. Whitlock G, Lewington S, Mhurchu CN. Coronary heart disease and body mass index: a systematic review of the evidence from larger prospective cohort studies. Semin Vasc Med 2002; 2(4):369-381.
60. Park HS, Song YM, Cho SI. Obesity has a greater impact on cardiovascular mortality in younger men than in older men among non-smoking Koreans. Int J Epidemiol 2005(Nov 3)(E-pub ahead of print).
61. Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003; 289(2):187-193.
62. Morse SA, Bravo PE, Morse MC, Reisin E. The heart in obesity-hypertension. Expert Rev Cardiovasc Ther 2005; 3(4):647-658.
63. Kinner B, Goos H, Ewers P, et al. The relation of anthropometric parameters and echocardiography findings in the evaluation of left ventricular form and function in extreme obesity. Z Gesamte Inn Med 1989; 44(5):152-157.
64. Duflou J, Virmani R, Rabin I, et al. Sudden death as a result of heart disease in morbid obesity. Am Heart J 1995; 130(2):306-313.
65. Kirby IJ, Howard EC. Propofol in a morbidly obese patient. Anaesthesia 1987; 42(10):1125-1126.
66. Paul DR, Hoyt JL, Boutros AR. Cardiovascular and respiratory changes in response to change of posture in the very obese. Anesthesiology 1976; 45(1):73-78.
67. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143(10):722-728. Summary for patients in:.
68. Ann Intern Med 2005; 143(10):I70.
69. Ann Intern Med 2005; 143(10):I72.
70. Festi D, Colecchia A, Sacco T, et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5(1):27-42.
71. Papadia FS, Marinari GM, Camerini G, et al. Liver damage in severely obese patients: a clinical-biochemical-morphologic study on 1,000 liver biopsies. Obes Surg 2004; 14(7):952-958.
72. Vaughan RW, Bauer S, Wise L. Volume and pH of gastric juice in obese patients. Anesthesiology 1975; 43(6):686-689.
73. Greenberg I. Psychological aspects of bariatric surgery. Nutr Clin Pract 2003; 18(2):124-130.
74. Beers RA, Roizen MF. Preoperative evaluation of the patient for bariatric surgery. In: Alvarez AO, ed. Morbid Obesity: Perioperative Management. Part 3. 1st ed. Cambridge, England: Cambridge University Press 2004:9.
75. Oberg B, Poulsen TD. Obesity: an anaesthetic challenge. Acta Anaesthesiol Scand 1996; 40(2):191-200.
76. Fraley MA, Birchem JA, Senkottaiyan N, Alpert MA. Obesity and the electrocardiogram. Obes Rev 2005; 6(4):275-281.
77. Daniel KR, Courtney DM, Kline JA. Assessment of cardiac stress from massive pulmonary embolism with 12-lead ECG. Chest 2001; 120(2):474-481.
78. Bossone E, Paciocco G, Iarussi D, et al. The prognostic role of the ECG in primary pulmonary hypertension. Chest 2002; 121(2):513-518.
79. Juvin P, Blarel A, Bruno F, Desmonts JM. Is peripheral line placement more difficult in obese than in lean patients? Anesth Analg 2003; 96(4):1218.
80. Gilbert TB, Seneff MG, Becker RB. Facilitation of internal jugular venous cannulation using an audio-guided Doppler ultrasound vascular access device: results from a prospective, dual-center, randomized, crossover clinical study. Crit Care Med 1995; 23:60-65.
81. Brodsky JB. Anesthetic management of the morbidly obese patient. Int Anesthesiol Clin 1986; 24(1):93-103.
82. Schumann R, Shikora S, Weiss JM, et al. A comparison of multimodal perioperative analgesia to epidural pain management after gastric bypass surgery. Anesth Analg 2003; 96(2):469-474.
83. Hood DD, Dewan DM. Anesthetic and obstetric outcome in morbidly obese parturients. Anesthesiology 1993; 79(6):1210-1218.
84. Buckley FP, Robinson NB, Simonowitz DA, Dellinger EP. Anaesthesia in the morbidly obese. A comparison of anaesthetic and analgesic regimens for upper abdominal surgery. Anaesthesia 1983; 38(9):840-851.
85. Charghi R, Backman S, Christou N, et al. Patient controlled i.v. analgesia is an acceptable pain management strategy in morbidly obese patients undergoing gastric bypass surgery. A retrospective comparison with epidural analgesia. Can J Anaesth 2003; 50(7):672-678.
86. Hodgkinson R, Husain FJ. Obesity, gravity, and spread of epidural anesthesia. Anesth Analg 1981; 60(6):421-424.
87. Taivainen T, Tuominen M, Rosenberg PH. Influence of obesity on the spread of spinal analgesia after injection of plain 0.5% bupivacaine at the L3-4 or L4-5 interspace. Br J Anaesth 1990; 64(5):542-546.
88. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94(4):750-759.
89. Bauer K. Hypercoagulable states. Hematology 2005; 10(suppl 1):39.
90. Nguyen NT, Owings JT, Gosselin R, et al. Systemic coagulation and fibrinolysis after laparoscopic and open gastric bypass. Arch Surg 2001; 136(8):909-916.
91. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 2005; 15(10):1368-1374.
92. Fox GS, Whalley DG, Bevan DR. Anaesthesia for the morbidly obese. Experience with 110 patients. Br J Anaesth 1981; 53(8):811-816.
93. Brodsky JB, Lemmens HJ, Brock-Utne JG, et al. Morbid obesity and tracheal intubation. Anesth Analg 2002; 94(3):732-736.
94. Collins JS, Lemmens HJ, Brodsky JB, et al. Laryngoscopy and morbid obesity: a comparison of the "sniff" and "ramped" positions. Obes Surg 2004; 14(9):1171-1175.
95. Brodsky JB, Lemmens HJ, Brock-Utne JG, et al. Anesthetic considerations for bariatric surgery: proper positioning is important for laryngoscopy. Anesth Analg 2003; 96(6):1841-1842.
96. Warner MA, Warner DO, Harper CM, et al. Ulnar neuropathy in medical patients. Anesthesiology 2000; 92(2):613-615.
97. Warner MA, Warner DO, Matsumoto JY, et al. Ulnar neuropathy in surgical patients. Anesthesiology 1999; 90(1):54-59.
98. Fritzlen T, Kremer M, Biddle C. The AANA Foundation Closed Malpractice Claims Study on nerve injuries during anesthesia care. AANA J 2003; 71(5):347-352.
99. Slepchenko G, Simon N, Goubaux B, et al. Performance of target-controlled sufentanil infusion in obese patients. Anesthesiology 2003; 98(1):65-73.
100. Casati A, Putzu M. Anesthesia in the obese patient: pharmacokinetic considerations. J Clin Anesth 2005; 17(2):134-145.
101. Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89(3):562-573.
102. Servin F, Farinotti R, Haberer JP, Desmonts JM. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiology 1993; 78(4):657-665.
103. Kakinohana M, Tomiyama H, Matsuda S, Okuda Y. Target-controlled propofol infusion for general anesthesia in three obese patients. Masui 2000; 49(7):732-735.
104. Saijo H, Nagata O, Kitamura T, et al. Anesthetic management of a hyper-obese patient by target-controlled infusion (TCI) of propofol and fentanyl. Masui 2001; 50(5):528-531.
105. Jung D, Mayersohn M, Perrier D, et al. Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology 1982; 56(4):269-274.
106. Dundee JW, Hassard TH, McGowan WA, Henshaw J. The 'induction' dose of thiopentone. A method of study and preliminary illustrative results. Anaesthesia 1982; 37(12):1176-1184.
107. Martinotti R, Vassallo C, Ramaioli F, et al. Anesthesia with sevoflurane in bariatric surgery. Obes Surg 1999; 9(2):180-182.
108. Arain SR, Barth CD, Shankar H, Ebert TJ. Choice of volatile anesthetic for the morbidly obese patient: sevoflurane or desflurane. J Clin Anesth 2005; 17(6):413-419.
109. Strum EM, Szenohradszki J, Kaufman WA, et al. Emergence and recovery characteristics of desflurane versus sevoflurane in morbidly obese adult surgical patients: a prospective, randomized study. Anesth Analg 2004; 99(6):1848-1853.
110. De Baerdemaeker LE, Struys MM, Jacobs S, et al. Optimization of desflurane administration in morbidly obese patients: a comparison with sevoflurane using an 'inhalation bolus' technique. Br J Anaesth 2003; 91(5):638-650.
111. Casati A, Torri G. Cardiovascular stability during inhalational anaesthesia in morbidly obese patients: which is better, sevoflurane or desflurane? Br J Anaesth 2004; 93(1):153-154; author reply 154-155.
112. Brodsky JB, Lemmens HJ, Collins JS, et al. Nitrous oxide and laparoscopic bariatric surgery. Obes Surg 2005; 15(4):494-496.
113. Schulte-Sasse U, Hess W, Tarnow J. Pulmonary vascular responses to nitrous oxide in patients with normal and high pulmonary vascular resistance. Anesthesiology 1982; 57(1):9-13.
114. Hilgenberg JC, McCammon RL, Stoelting RK. Pulmonary and systemic vascular responses to nitrous oxide in patients with mitral stenosis and pulmonary hypertension. Anesth Analg 1980; 59(5):323-326.
115. Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet 1999; 36(1):27-40.
116. Roy JJ, Varin F. Physicochemical properties of neuromuscular blocking agents and their impact on the pharmacokinetic-pharmacodynamic relationship. Br J Anaesth 2004; 93(2):241-248.
117. Leykin Y, Pellis T, Lucca M, et al. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg 2004; 99(4):1086-1089.
118. Varin F, Ducharme J, Theoret Y, et al. Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Clin Pharmacol Ther 1990; 48(1):18-25.
119. Leykin Y, Pellis T, Lucca M, et al. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004; 99(4):1090-1094 (table of contents).
120. Weinstein JA, Matteo RS, Ornstein E, et al. Pharmacodynamics of vecuronium and atracurium in the obese surgical patient. Anesth Analg 1988; 67(12):1149-1153.
121. Choi YK, Brolin RE, Wagner BK, et al. Efficacy and safety of patient-controlled analgesia for morbidly obese patients following gastric bypass surgery. Obes Surg 2000; 10(2):154-159.
122. Fujioka K. Follow-up of nutritional and metabolic problems after bariatric surgery. Diabetes Care 2005; 28(2):481-484.
123. Ocon Breton J, Perez Naranjo S, Gimeno Laborda S, et al. Effectiveness and complications of bariatric surgery in the treatment of morbid obesity. Nutr Hosp 2005; 20(6):409-414.
124. 2-receptor antagonists. Med Toxicol Adverse Drug Exp 1988; 3(6):430-448.
125. De Paz R, Hernandez-Navarro F. Management, prevention and control of pernicious anemia. Nutr Hosp 2005; 20(6):433-435.
126. Slater GH, Ren CJ, Siegel N, et al. Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastrointest Surg 2004; 8(1):48-55; discussion 54-55.
127. Reijnen MM, Janssen IM. Cardiac arrhythmias after laparoscopic banding. Obes Surg 2004; 14(1):139-141.